Status:
COMPLETED
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diphtheria
Acellular Pertussis
Eligibility:
All Genders
6-8 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and immunogenicity of a booster dose of GSK Biologicals' reduced antigen content diphtheria, tetanus, acellular pertussis (dTpa) vaccine - Boostrix in comparison wi...
Eligibility Criteria
Inclusion
- A male or female between, and including, 6-8 years of age at the time of vaccination,
- Written informed consent obtained from the parent or guardian of the subject,
Exclusion
- Subjects who have received a total of 4 doses of DTP vaccine in the first 2 years of life, subjects who have received previous DTP booster vaccination since administration of the fourth dose of vaccine in second year of life can not participate.
- Subjects with history of diphtheria, pertussis or tetanus diseases can not participate.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT00452686
Start Date
March 1 2007
End Date
May 1 2007
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Suining, China